One-on-One with Martin Shkreli, co-founder of the hedge fund MSMB Capital Management, co-founder and former chief executive officer (CEO) of the biotechnology firm Retrophin, and founder and former CEO of Turing Pharmaceuticals. In September 2015, Shkreli received widespread criticism when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price by 5,556 percent (from US$13.5 to US$750 per tablet), leading him to be referred to by media as the "most hated man in America."

Say what you want of Shkreli, but he doesn't bend to public opinion, and is not apologetic for what he stands for. 


Leave a Reply